Dr. David Rees, Vice President Medicinal Chemistry, will be making Astex’s first public disclosure of the full chemical structure of AT7519 during his talk in the ‘Meet-the-Expert Session’. AT7519 is a potent cell cycle inhibitor that targets key cyclin-dependent kinases and is in Phase I studies in patients with solid tumours with additional Phase II studies planned for 2008.
In addition, Astex will present data which demonstrates the activity of its multi-targeted kinase inhibitor, AT9283, in Chronic Myelogenous Leukemia models, particularly cell lines and patient samples that are resistant to existing therapies such as Sprycel®, Tasigna® and Gleevec®. AT9283 is currently in Phase I trials in patients with solid tumours and Phase I/II trials in patients with leukamias where early clinical activity has been observed.
Astex will also make the first disclosure of uniquely selective inhibitors of the Fibroblast Growth Factor Receptor (FGFr) kinase, which have shown potent antitumour activity in FGFr dependent xenograft models. The wide number of cancers that are associated with FGFr dependence include breast, colorectal, endometrial, bladder, multiple melanoma, prostate and angiogenesis.
Astex has a further five internal drug discovery programmes and is pursuing an additional five projects in partnership with leading pharmaceutical companies including Novartis, AstraZeneca, Bayer Schering and Boehringer Ingelheim.
Meet-the-Expert Session at the 2008 AACR Annual Meeting
Session Title: Fragment Based Drug Discovery Session Date: Monday 14 April, 2008, 7:00 AM to 8:00 AM Session Location: Room 11A-B
Poster Presentations at the 2008 AACR Annual Meeting
Poster Title: AT9283, a potent inhibitor of Bcr-Abl T315I, is active in CML models Session Date: Monday, April 14, 2008, 1:00 PM Session ID: Clinical Research 10 Permanent Abstract Number: 2820 Poster Title: Development of inhibitors of the fibroblast growth factor receptor (FGFr) kinase using a fragment based approach Session Date: Sunday, April 13, 2008, 1:00 PM Session ID: Experimental and Molecular Therapeutics 14 Permanent Abstract Number: 1545
Contacts Astex Therapeutics Limited Romaine Miles Corporate Communications Email: r.miles@astex-therapeutics.com Tel: +44 (0) 1223 226200 Web: www.astex-therapeutics.com
